News Center

Home page

Peak Report

News reports

Seize the opportunity, strive for a new high point of cement performance, find the right track, break through the bottleneck period of the pharmaceutical company, the chairman of the board of directors points out the direction for the work in the coming year.

Release time:

2022-02-08

2021 held on February 26 , Jiang Xiaomeng, secretary of the party Committee and chairman of the group company, made a summary speech entitled "seize the opportunity and strive for a new high point in cement performance" in view of the current market situation and existing problems faced by the company. Find the track and break through the bottleneck period of pharmaceutical companies, pointing out direction and requirements for the company's work in 2022 . Jiang Xiaomeng pointed out that in

2021

, the company achieved relatively ideal operating results in a complex market environment, which is not only the foundation laid by the company's industrial structure adjustment and capital investment in recent years, but also the result of the joint efforts of management departments at all levels and employees of production enterprises. The general manager's work report comprehensively analyzes and expounds the company's current business situation and future direction of efforts, which is the arrangement made by the management of the group company after close analysis and careful consideration. I hope that the management team of each enterprise will seriously understand and implement it, so as to better complete all the work in the new year. When talking about the work direction of

2022

, Jiang Xiaomeng summed it up in two sentences, namely, "seize the opportunity and strive for a new high in cement performance; Find the right track and break through the bottleneck period of pharmaceutical companies". Jiang Xiaomeng said that the Central Economic Work Conference pointed out that the economic work in

2022

should "take the lead in stability and seek progress in stability" and "continue to implement a proactive fiscal policy and a prudent monetary policy". The economic work conferences of all provinces have also released relevant positive signals, which shows that the government will take measures to stimulate the economy; as the epidemic situation in major foreign power coal supply countries is relatively under control, energy prices have also entered a downward channel, which will reduce the cost pressure of raw fuel materials for cement enterprises. In recent years, cement enterprises under the peak have continuously increased their investment in equipment and technology upgrading, and cost control is expected to be significantly improved. The superposition of these internal and external factors will bring opportunities to the peak cement plate. Therefore, all cement enterprises should take stock of the situation, seize the favorable opportunity and do a good job in the homework of "cement ", that is, extend the cement industry chain to the upstream and downstream, realize vertical integration, and take aggregate, machine-made sand and solid and hazardous waste treatment as the new profit-making points of cement plate, so as to create better business performance. For the peak medicine sector, Jiang Xiaomeng believes that peak medicine

has developed over the years, accumulated a number of talents and technologies, cultivated some new products, and its product structure has been continuously adjusted according to market changes. Although the current centralized band procurement has an impact on drug prices, the sales growth of the winning varieties is also conducive to the dilution of costs, which has been reflected in the market sales of peak pharmaceutical olopatadine eye drops. From the perspective of industry development trends, as the global failure rate of new drug research and development is getting higher and higher, and it is becoming more and more difficult to develop new targets, improved new drugs that upgrade existing drugs may be another blue ocean for pharmaceutical companies. At the same time, the continuous improvement of environmental protection requirements make API production resources increasingly scarce, the advantages of the North Carolina API base of Peak Pharmaceuticals will become more and more obvious. Therefore, the new track of peak pharmaceutical industry should be developed to eye drops and ophthalmic drugs, to improved new drugs, and to the integration of raw materials and preparations. Jiang Xiaomeng said that while identifying its own advantages and efforts, it is also necessary to see its own shortcomings. There is still room for improvement in many indicators and labor productivity of Jianfeng cement enterprises, and the research and development speed of Jianfeng Pharmaceutical products is not as fast as expected, which requires management teams at all levels to break away from their inherent thinking and further improve their ability and methods of solving problems in terms of management, communication, coordination and team unity. Through the joint efforts of all employees and doing a good job in accordance with the company's deployment, we will certainly achieve better performance in the new year. (this newspaper reporter)

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页